The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in ...

AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.

Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could ...

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior ...

Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn ...